Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial.

A post hoc analysis of CALGB/SWOG 80702 examined whether postoperative ctDNA, measured with Signatera, predicted survival with adjuvant celecoxib plus chemotherapy in stage III colon cancer.

JAMA OncologyPubMed 41343176DOI 10.1001/jamaoncol.2025.5144